Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document†


Erasmus University Medical Center, PO Box 2040, 3000 CA Rotterdam, Netherlands

* Corresponding author. Tel: +31-010-7035784; fax: +31-010-7032358; e-mail: a.kappetein@erasusmc.nl.

Received 28 June 2012; received in revised form 24 July 2012; accepted 26 July 2012

Abstract

OBJECTIVES: The aim of the current Valve Academic Research Consortium (VARC)-2 initiative was to revisit the selection and definitions of transcatheter aortic valve implantation (TAVI) clinical endpoints to make them more suitable to the present and future needs of clinical trials. In addition, this document is intended to expand the understanding of patient risk stratification and case selection.

BACKGROUND: A recent study confirmed that VARC definitions have already been incorporated into clinical and research practice and represent a new standard for consistency in reporting clinical outcomes of patients with symptomatic severe aortic stenosis (AS) undergoing TAVI. However, as the clinical experience with this technology has matured and expanded, certain definitions have become unsuitable or ambiguous.

METHODS AND RESULTS: Two in-person meetings (held in September 2011 in Washington, DC, USA, and in February 2012 in Rotterdam, Netherlands) involving VARC study group members, independent experts (including surgeons, interventional and non-interventional cardiologists, imaging specialists, neurologists, geriatric specialists, and clinical trials) and industry representatives, provided much of the substantive discussion from which this VARC-2 consensus manuscript was derived. This document provides an overview of risk assessment and patient stratification that need to be considered for accurate patient inclusion in studies. Working groups were assigned to define the following clinical endpoints: mortality, stroke, myocardial infarction, bleeding complications, acute kidney injury, vascular complications, conduction disturbances and arrhythmias, and a miscellaneous category including relevant complications not previously categorized. Furthermore, comprehensive echocardiographic recommendations are provided for the evaluation of prosthetic valve (dys)function. Definitions for the quality of life assessments are also reported. These endpoints formed the basis for several recommended composite endpoints.

CONCLUSIONS: This VARC-2 document has provided further standardization of endpoint definitions for studies evaluating the use of TAVI, which will lead to improved comparability and interpretability of the study results, supplying an increasingly growing body of evidence with respect to TAVI and/or surgical aortic valve replacement. This initiative and document can furthermore be used as a model during current endeavours of applying definitions to other transcatheter valve therapies (for example, mitral valve repair).

INTRODUCTION

The first Valve Academic Research Consortium (VARC) consensus manuscript was published in January 2011 with the goal of achieving consensus for (i) selecting appropriate clinical endpoints reflecting device, procedure and patient-related effectiveness and safety, and (ii) standardizing definitions for single and composite clinical endpoints, for transcatheter aortic valve implantation (TAVI) clinical trials [1, 2]. A recent pooled analysis, which included 3519 patients from 16 unique studies, confirms that VARC definitions have already been incorporated into clinical and research practice and represent a new standard for consistency in reporting clinical outcomes of patients with symptomatic
severe aortic stenosis (AS) undergoing TAVI [3]. However, as the clinical experience with this technology has matured and expanded, certain definitions have become unsuitable or ambiguous [3–7]. The aim of the current VARC was therefore to revisit the selection and definitions of TAVI-related clinical endpoints to make them more suitable to the present and future needs of clinical trials. In addition, this document is intended to expand the understanding of patient risk stratification and case selection.

Similar to the VARC-1 process, two in-person meetings (held in September 2011 in Washington, DC, USA, and in February 2012 in Rotterdam, Netherlands) involving VARC study group members, independent experts (including surgeons, interventional and non-interventional cardiologists, imaging specialists, neurologists, geriatric specialists, and clinical trialists), the US Food and Drug Administration (FDA), and industry representatives, provided much of the substantive discussion from which this VARC-2 consensus manuscript was derived (see Appendixes).

RISK SCORES AND COMORBIDITIES

Risk stratification of patients is crucial to identifying appropriate candidates for specific cardiac procedures. The EuroSCORE and Society of Thoracic Surgeons (STS) score are the most widely used risk scores to predict operative mortality in cardiac surgery. These models were developed and validated in a standard surgical risk population. The predictive power of both models is therefore suboptimal in high-risk patients with valvular disease, although the STS score has shown to outperform the Logistic EuroSCORE [8]. These models are even more limited in application to patients who are considered at prohibitive risk for cardiac surgery, a cohort that could particularly benefit from TAVI. Current models could be improved by the addition of specific clinical and anatomical variables that affect mortality [9]. As an example, the presence of a porcelain aorta and frailty are important factors not included in either risk model but are routinely considered during patient evaluation (Fig. 1 and Table 1).

Perhaps the most important patient characteristic not included in current risk models is frailty [10]. Frailty is frequently assessed subjectively based upon an informal 'eyeball test'. However, physical performance assessments such as gait speed and grip strength are more objective performance measures that may capture an individual’s overall functional status [11]. These continuous measures are reproducible and can be re-assessed at various time points. In addition, they require no language translation. Assessments of cognition, weight (loss), activity level, and independence in the activities of daily living provide additional information on the overall health state of the individual [11]. These limitations are more often found in patients with a high comorbidity burden and may co-exist with certain laboratory findings (e.g. low serum albumin, elevated inflammatory markers, anaemia) that further reflect the health state and physiological reserve of the frail patient.

Baseline evaluation of the presence of cognitive dysfunction (mild cognitive impairment or dementia) has also emerged as an essential part of the initial risk stratification, especially in older populations, where the risk, benefit, and cost-effectiveness of invasive procedures must be weighed judiciously. Pre-procedural cognitive assessment may also help avoid attributing post-procedural mental status changes to stroke categories. Among the several clinically established rating scales [e.g. Mini-Mental State Examination, modified Telephone Interview of Cognitive Status (TICS-M), Clinical Dementia Rating Scale], [12] there is no particular standard for TAVI. Nevertheless, some systematic cognitive assessment by neuropsychological experts should be a part of the initial heart team evaluation.

Table 1 provides an overview of these and other risk factors (Figs 1–3) and VARC-2 recommendations on how each should be assessed. In clinical trials, it will be important to capture variables that predict extreme operative risk and to standardize the evaluation criteria and process. This will help to determine which subsets of patients are likely to benefit from TAVI treatment.

PATIENT STRATIFICATION: THE HEART TEAM APPROACH

Valve Academic Research Consortium-2 recommends the use of a heart team for patient evaluation. The heart team should

Figure 1: Porcelain aorta or severely atherosclerotic aorta.
The heart team should agree on an estimated 30-day mortality risk for each patient based upon integrating a careful clinical assessment and utilizing appropriate risk prediction scoring systems, preferably the STS score. Surgical mortality risk strata are difficult to precisely assign, but an estimated 30-day mortality of <4% is considered low risk, 4–10% is intermediate risk, >10% is high risk, and >15% is very high risk. A patient is considered at extreme risk if at least two cardiovascular surgeons from a tertiary centre of excellence deny surgery because of

<table>
<thead>
<tr>
<th>Table 1: Risk factors not captured by traditional risk scores</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Co-morbidities</strong></td>
</tr>
<tr>
<td>Porcelain aorta or severely atherosclerotic aorta</td>
</tr>
<tr>
<td>Frailty</td>
</tr>
<tr>
<td>Severely liver disease/cirrhosis</td>
</tr>
<tr>
<td>Hostile chest</td>
</tr>
<tr>
<td>IMA or other critical conduit(s) crossing midline and/or adherent to posterior table of sternum</td>
</tr>
<tr>
<td>Severe pulmonary hypertension</td>
</tr>
<tr>
<td>Severe right ventricular dysfunction</td>
</tr>
</tbody>
</table>

CT: computed tomography; MELD: Model for End-Stage Liver Disease; INR: international normalized ratio; IMA: internal mammary artery; PA: pulmonary artery.

*Variable with respect to age and gender without validated scientific thresholds.

*Rudski et al. [71].
prohibitive operative risks, estimated to be a combined >50% risk of irreversible morbidity or mortality [13]. In addition to the specific risk factors that can prohibit patients from undergoing TAVI or surgical aortic valve replacement (SAVR) (Table 1), the operative risk assessment is also important to identify patients who are likely not to benefit from either TAVI or SAVR (the so-called ‘futility’ category of high-risk patients). An expected improvement in the quality of life (QOL) may further be necessary to identify treatment responders vs. non-responders. Individualized life expectancy assumptions should be incorporated by the heart team in the clinical decision-making process as a central factor in weighing the risk–benefit ratio. Prognostic indices of life expectancy may play a central role in moving beyond arbitrary age-based cut-offs [14].

The most important role of the heart team is to provide customized management decisions for common and unusual clinical scenarios in terms of patient selection, procedural performance, and complication management. An example is the frequent situation of severe AS and concomitant coronary artery disease (CAD). The complexity of CAD and appropriate revascularization strategies in the setting of AS should be determined by consensus from interventional cardiologists and cardiovascular surgeons [15, 16]. In new TAVI clinical trials, angiographic risk scores (e.g. SYNTAX score) may be utilized to help determine the complexity of CAD, as a basis for the inclusion in the trial. Thresholds for coronary revascularization and the choice for a staged or concomitant PCI with TAVI should be guided by the complexity of the CAD and other factors as determined by the heart team [17, 18]. In general, the plan to deal with other co-existing conditions [such as atrial fibrillation (AF), other valvular lesions, and other congenital lesions] should be pre-specified and all complications encountered in the treatment of associated conditions (including treatment after the TAVI procedure) should be captured. Such thorough pre-procedural assessment is also valuable in discriminating new post-procedural complications from simple exacerbations of pre-existing conditions.

**CLINICAL ENDPOINTS**

**Mortality**

In addition to the original VARC definitions, VARC-2 recommends the collection of *immediate procedural mortality* to capture intra-procedural events that result in immediate or consequent death ≤72 h post-procedure. Taking into account the surgical literature, *procedural mortality* consists of all-cause mortality within 30 days or during index procedure hospitalization—if the postoperative length of stay is longer than 30 days.

The cause of death should be captured, based on a careful review of narrative summaries and source material. All-cause, cardiovascular, and non-cardiovascular mortality should be reported after 30 days during the follow-up (Table 2). In determining the cause of death, the adjudication committee should consider the
clinical context at the time of the index procedure and during the time interval leading up to death. All efforts (including the use of national death registries) should be made to identify, precisely characterize, and appropriately classify any death.

### Myocardial infarction

Myocardial injury as determined by a significant rise in cardiac biomarkers occurs frequently following TAVI, and a significant magnitude of myocardial injury has been associated with worse outcomes [19]. Valve Academic Research Consortium-2 recommends the systematic collection of biomarkers of myocardial injury prior to the procedure, within 12–24 h after the procedure, at 24 h thereafter, at 72 h or at discharge, and, if still elevated, daily until values show a decline. Similar to the previous VARC recommendations, the definition of peri-procedural (≤72 h following TAVI) MI will be based on a combination of clinical criteria and cardiac biomarkers, however, the threshold values have been adjusted (Table 3). Acute ischaemic events occurring after 72 h should be considered spontaneous myocardial infarctions and defined in accordance with the universal MI guidelines [20].

### Stroke

With increasing attention to stroke as an important peri-procedural complication of TAVI, [21] the FDA has emphasized the need for an accurate assessment of stroke and has participated actively in recommending specific details of the VARC-2 definitions. In an attempt to further align with the fundamental definitions now endorsed by the FDA, [22] consensus was reached at VARC-2 to further refine the definition of stroke and recommend the use of these definitions in future TAVI clinical trials (Table 4). The definitions endorsed by the FDA are intended to apply to a wide range of clinical trials and to enable those trials to assess the clinically relevant consequences of vascular brain injury for determining the safety or effectiveness of an intervention.

---

**Table 2: Mortality**

<table>
<thead>
<tr>
<th>Category</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>All-cause mortality</td>
<td>Any death in which the primary cause of death is clearly related to another condition (e.g. trauma, cancer, suicide)</td>
</tr>
<tr>
<td>Cardiovascular mortality</td>
<td>Any of the following criteria:</td>
</tr>
<tr>
<td></td>
<td>Death due to proximate cardiac cause (e.g. myocardial infarction, cardiac tamponade, worsening heart failure)</td>
</tr>
<tr>
<td></td>
<td>Death caused by non-coronary vascular conditions such as neurological events, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular disease</td>
</tr>
<tr>
<td></td>
<td>All procedure-related deaths, including those related to a complication of the procedure or treatment for a complication of the procedure</td>
</tr>
<tr>
<td></td>
<td>All valve-related deaths including structural or non-structural valve dysfunction or other valve-related adverse events</td>
</tr>
<tr>
<td></td>
<td>Death of unknown cause</td>
</tr>
<tr>
<td></td>
<td>Non-cardiovascular mortality</td>
</tr>
</tbody>
</table>

**Table 3: Myocardial infarction**

<table>
<thead>
<tr>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peri-procedural MI (≤72 h after the index procedure)</td>
</tr>
<tr>
<td>New ischaemic symptoms (e.g. chest pain or shortness of breath), or new ischaemic signs (e.g. ventricular arrhythmias, new or worsening heart failure, new ST-segment changes, haemodynamic instability, new pathological Q-waves in at least two contiguous leads, imaging evidence of new loss of viable myocardium or new wall motion abnormality) AND Elevated cardiac biomarkers (preferable CK-MB) within 72 h after the index procedure, consisting of at least one sample post-procedure with a peak value exceeding 15× as the upper reference limit for troponin or 5× for CK-MB.* If cardiac biomarkers are increased at baseline (&gt;99th percentile), a further increase in at least 50% post-procedure is required AND the peak value must exceed the previously stated limit</td>
</tr>
<tr>
<td>Spontaneous MI (&gt;72 h after the index procedure)</td>
</tr>
<tr>
<td>Any one of the following criteria:</td>
</tr>
<tr>
<td>Detection of rise and/or fall of cardiac biomarkers (preferably troponin) with at least one value above the 99th percentile URL, together with the evidence of myocardial ischaemia with at least one of the following: Symptoms of ischaemia: ECG changes indicative of new ischaemia [new ST-T changes or new left bundle branch block (LBBB)] New pathological Q-waves in at least two contiguous leads Imaging evidence of a new loss of viable myocardium or new wall motion abnormality Sudden, unexpected cardiac death, involving cardiac arrest, often with symptoms suggestive of myocardial ischaemia, and accompanied by presumably new ST elevation, or new LBBB, and/or evidence of fresh thrombus by coronary angiography and/or at autopsy, but death occurring before blood samples could be obtained, or at a time before the appearance of cardiac biomarkers in the blood</td>
</tr>
<tr>
<td>Pathological findings of an acute myocardial infarction</td>
</tr>
</tbody>
</table>

*Previously in the original VARC it was 10× and 5× for troponin and CK-MB, respectively

---

Stroke is defined as an acute episode of focal or global neurological dysfunction caused by the brain, spinal cord, or retinal vascular injury as a result of haemorrhage or infarction. Stroke may be classified as ischaemic or haemorrhagic with appropriate subdefinitions. Ischaemic stroke is defined as an acute episode of focal cerebral, spinal, or retinal dysfunction caused by infarction of central nervous system tissue. Haemorrhagic stroke is defined as an acute episode of focal or global cerebral or spinal dysfunction caused by intraparenchymal, intraventricular, or subarachnoid haemorrhage. A stroke may be classified as ‘undetermined’ if there is insufficient information to allow the categorization as ischaemic or haemorrhagic.

An entity closely related to an ischaemic stroke that should be assessed is a transient ischaemic attack (TIA). Transient ischaemic attack is defined as a transient episode of focal neurological dysfunction caused by the brain, spinal cord, or retinal ischaemia, without acute infarction. The difference between TIA and ischaemic stroke is the presence of tissue damage on neuro-imaging studies or new sensory–motor deficit persisting >24 h. By definition, a TIA does not produce a lasting disability.

Valve Academic Research Consortium-2 recognizes that an assessment of stroke is incomplete without an appropriate measurement of the disability resulting from the stroke. Valve Academic Research Consortium-2 recommends the use of the modified Rankin Scale (mRS) to assess this clinical disability.
Table 4: Stroke and TIA

<table>
<thead>
<tr>
<th>Diagnostic criteria</th>
<th>Stroke classification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute episode of a focal or global neurological deficit with at least one of the following: change in the level of consciousness, hemiplegia, hemiparesis, numbness, or sensory loss affecting one side of the body, dysphasia or aphasia, hemianopia, amaurosis fugax, or other neurological signs or symptoms consistent with stroke.</td>
<td>Ischaemic: an acute episode of focal cerebral, spinal, or retinal dysfunction caused by infarction of the central nervous system tissue</td>
</tr>
<tr>
<td>Stroke: duration of a focal or global neurological deficit ≥24 h; OR &lt;24 h if available neuroimaging documents a new haemorrhage or infarct; OR the neurological deficit results in death.</td>
<td>Haemorrhagic: an acute episode of focal or global cerebral or spinal dysfunction caused by intraparenchymal, intraventricular, or subarachnoid haemorrhage</td>
</tr>
<tr>
<td>TIA: duration of a focal or global neurological deficit &lt;24 h, any variable neuroimaging does not demonstrate a new haemorrhage or infarct.</td>
<td>A stroke may be classified as undetermined if there is insufficient information to allow categorization as ischaemic or haemorrhagic</td>
</tr>
<tr>
<td>No other readily identifiable non-stroke cause for the clinical presentation (e.g. brain tumour, trauma, infection, hypoglycaemia, peripheral lesion, pharmacological influences), to be determined by or in conjunction with the designated neurologist.</td>
<td>Confirmation of the diagnosis by at least one of the following Neurologist or neurosurgical specialist</td>
</tr>
<tr>
<td>Neuroimaging procedure (CT scan or brain MRI), but stroke may be diagnosed on clinical grounds alone.</td>
<td>Neuroimaging (CT scan or brain MRI).</td>
</tr>
</tbody>
</table>

Stroke definitions:

- Disabling stroke: an mRS score of 2 or more at 90 days and an increase in at least one mRS category from an individual's pre-stroke baseline.
- Non-disabling stroke: an mRS score ≤2 at 90 days or one that does not result in an increase in at least one mRS category from an individual's pre-stroke baseline.

mRS: modified Rankin Scale.

a Patients with non-focal global encephalopathy will not be reported as a stroke without unequivocal evidence of cerebral infarction-based upon neuroimaging studies (CT scan or brain MRI).

b Modified Rankin Scale assessments should be made by qualified individuals according to a certification process in accordance with the 2018 edition of the National Institute of Neurological Disorders and Stroke (NINDS) guidelines for stroke and TIA.

Although brain imaging (typically, MRI for acute and chronic ischaemia and haemorrhage, and CT for acute and chronic haemorrhage and chronic ischaemia) is often used to supplement the clinical diagnosis of stroke, [26] a diagnosis of stroke may be made on clinical grounds alone. Valve Academic Research Consortium-2 recognizes that stroke symptoms are protean and not well suited to a pre-specified itemized listing. Accordingly, VARC-2 recommends that a vascular neurologist experienced in clinical trials involving stroke be included in all phases of trial planning, execution, and monitoring, including involvement in the Clinical Events Committee and the Data and Safety Monitoring Board.

New insights into the timing of events show delayed or late occurrence of strokes, beyond the early post-implantation phase [27]. This may suggest that the cause of stroke is additionally related to other factors or patient susceptibilities and should necessitate active investigation of devices and adjunctive pharmacotherapy to reduce the frequency and severity of strokes after TAVI, including precise documentation of the use and dosage of antithrombotic and antiplatelet medication. Patient baseline characteristics (e.g. carotid stenosis) and postoperative complications (e.g. AF) need to be carefully documented to be able to identify the contributing causes of stroke.

Invasive stroke management (catheter-based intracranial intervention) is gaining an increasingly important role and may impact morbidity and mortality. Valve Academic Research Consortium-2 therefore recommends the ascertainment of any acute stroke management strategy (e.g. aspiration, thrombolysis, or conservative management).

Bleeding complications

Valve Academic Research Consortium-2 acknowledges the fact that the Bleeding Academic Research Consortium (BARC) recently convened and established standardized bleeding definitions for patients receiving antithrombotic therapy and undergoing coronary revascularization (PCI or CABG) [28, 29]. However, because the current definitions have been well adopted and shown to be accurate in predicting adverse events, [30] VARC-2 has chosen to maintain the original VARC definitions with BARC classifications (Table 5), recognizing that future validation of BARC criteria in this population may warrant revision of the current recommendations.

With respect to blood transfusions, it is critical to acknowledge that a bleeding complication has to be the result of overt bleeding and cannot be adjudicated based on blood transfusions alone.

Acute kidney injury

The original VARC definitions recommended the use of a modified version of the RIFLE classification. However, we now recommend using the AKIN system (Table 6), which is a modified version of RIFLE that has been adopted by many in the nephrology community, including the KDIGO initiative [31, 32]. As a result, acute kidney injury (AKI) can also be diagnosed according to urine output measures (Table 6).

In comparison with the original VARC, the timing for the diagnosis of AKI is extended from 72 h to 7 days. Patients who...
experience AKI should have follow-up renal function assessments after 7 days until stabilization.

**Vascular complications**

Table 7 lists VARC-2 definitions for major and minor vascular complications. Further clarifications of these definitions to supplement the original VARC document are as follows. Pre-planned surgical access or a planned endovascular approach to vascular closure (e.g. 'pre-closure') [33, 34] should be considered as part of the TAVI procedure and not as a complication, unless untoward clinical consequences are documented (e.g. bleeding complications, limb ischaemia, distal embolization, or neurological impairment). Unplanned endovascular stenting or surgical repair for any vascular complications during the index procedure without other clinical sequelae should be considered a minor vascular complication, except if associated with qualifying consequences (Table 7). Complications related to alternative access sites, including the left-ventricular apex, subclavian artery, or aorta should be systematically recorded. To ensure accurate capture of these elements, VARC-2 strongly recommends that detailed information regarding the access site and pre-planned vascular closure technique be recorded as well as the use of any additional unplanned access or closure techniques (surgical repair, endovascular stenting, or endovascular balloon therapy). Since many vascular complications will also result in a bleeding complication, events that meet VARC-2 definitions for both categories should be reported in both categories. Finally, VARC-2 recommends that all vascular complications be recorded as either access (e.g. iliac rupture) or non-access site-related
(e.g. ascending aorta dissection or rupture unless aortic access is used and the event originates from the cannulation site).

### Conduction disturbances and arrhythmias

Valve Academic Research Consortium-2 proposes the systematic collection of data on the frequency of implant-related new and/or worsened conduction disturbances and the incidence and indication for permanent pacemaker implantation (Table 8). In addition, the frequency of specific arrhythmias following TAVI should be recorded as they may result in prolonged hospitalization and impaired clinical outcomes. New-onset AF (or flutter) is diagnosed as any arrhythmia within hospitalization that has the ECG characteristics of atrial fibrillation (or flutter) and lasts sufficiently long to be recorded on a 12-lead ECG, or for at least 30 s on a rhythm strip [35]. The therapeutic approach to new-onset AF (spontaneous conversion, electrical or medical cardioversion, initiation of oral anticoagulation, and rate or rhythm control medications) and any clinical consequences should be thoroughly documented in the case report form.

<table>
<thead>
<tr>
<th>Table 8: Conduction disturbances and arrhythmias</th>
</tr>
</thead>
<tbody>
<tr>
<td>Up to 72 h, continuous rhythm monitoring is recommended in order to maximize the detection of arrhythmias</td>
</tr>
<tr>
<td>Data elements to be collected should include</td>
</tr>
<tr>
<td>Baseline conduction abnormalities, paroxysmal or permanent atrial fibrillation (or flutter), and the presence of permanent pacemaker*</td>
</tr>
<tr>
<td>Implant-related new or worsened cardiac conduction disturbance (new or worsened first-degree atrioventricular (AV) block, second-degree AV block (Mobitz I or Mobitz II), third-degree AV block, incomplete right bundle branch block, right bundle branch block, intraventricular conduction delay, left bundle branch block, left anterior fascicular block, or left posterior fascicular block, including block requiring a permanent pacemaker implant)</td>
</tr>
<tr>
<td>Persistent or transient high-degree AV block. High-grade AV block is persistent if it is present every time the underlying rhythm is checked</td>
</tr>
<tr>
<td>New permanent pacemaker implantation, with precision of the indication and the number of days post-implant of the placement of new permanent pacemaker</td>
</tr>
<tr>
<td>New-onset atrial fibrillation (or flutter)**</td>
</tr>
<tr>
<td>Any new arrhythmia resulting in haemodynamic instability or requiring therapy**</td>
</tr>
</tbody>
</table>

*Type of permanent pacemaker should be recorded (e.g. defibrillator, single vs. dual chamber, biventricular).  
**New-onset atrial fibrillation (or flutter) is diagnosed as any arrhythmia within hospitalization that has the ECG characteristics of atrial fibrillation (or flutter) and lasts sufficiently long to be recorded on a 12-lead ECG, or for at least 30 s on a rhythm strip.  
**Therapy includes electrical/medical cardioversion or initiation of a new medication (oral anticoagulation, rhythm, or rate controlling therapy).

Other TAVI-related complications

The original VARC document recommended the collection of a number of TAVI-related complications, but did not provide specific endpoint definitions for several endpoints. Valve Academic Research Consortium-2 recommends reporting any other complications related to the TAVI procedure, even those occurring less frequently, and provides formal VARC-2 definitions (Table 9) [36–38].

### Additional considerations

For studies or trials where the occurrence, prevention, or treatment of cerebral infarction is a fundamental feature (e.g. embolic protection devices) additional appropriate imaging in all or a subset of patients may be necessary to allow determination of effectiveness.

### VALVULAR FUNCTION

Valve Academic Research Consortium-2 maintains the original recommendations to use echocardiography as the primary imaging modality for the assessment of prosthetic valve function [39]. This should include the valve position, morphology, function, and evaluation of the left ventricle (LV) and right ventricle (RV) size and function. The suggested time points for routine follow-up transthoracic echocardiography (TTE) following valve implantation are: immediately (before discharge) following the implantation for transarterial approaches or within 30 days for transapical or transaortic approaches, 6 months following implantation, 1 year following implantation, and yearly thereafter. At these endpoints, prosthetic aortic valve stenosis and regurgitation should be reported.

### Transcatheter valve stenosis

The assessment of prosthetic valve stenosis should be an integrative process utilizing multiple parameters of valve function. Table 10 outlines the primary parameters used for assessing prosthetic valve function based on published guidelines [40]. Divergence from the guidelines is based on a number of studies, [41, 42] as well as methods used in large randomized control trials of TAVI [43, 44]. In addition, VARC-2 does not recommend using acceleration time, which is dependent on ventricular function and heart rate [42]. The limitation of flow-dependent parameters such as peak jet velocity or mean transprosthetic gradient is obvious, however, even flow-independent parameters such as the effective orifice area (EOA) and the Doppler velocity index (DVI) have limitations: (i) the absolute EOA does not account for the cardiac output requirements in relation to the patient’s body size; thus lower criteria should be used to define prosthetic valve stenosis in patients with BSA <1.6 m² (Table 10), (ii) the indexed EOA may overestimate the valve-related haemodynamic burden in obesity; hence, lower criteria may be more appropriate in patients with a body mass index ≥30 kg/m², (iii) DVI severity criteria are dependent on the left ventricular outflow tract (LVOT) size; thus a lower threshold may be more appropriate in patients with LVOT diameters of >25 mm. The EOA should generally be calculated with the use of the LVOT diameter and the velocity measured just underneath the apical margin of the valve stent [45, 46]. In cases where the landing zone of the stent is low in the LVOT, the diameter and velocity may both be measured in the proximal portion of the stent. Unlike the surgically implanted valve, the transcatheter
Table 9: Other TAVI-related complications

<table>
<thead>
<tr>
<th>Conversion to open surgery</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conversion to open sternotomy during the TAVI procedure secondary to any procedure-related complications</td>
</tr>
<tr>
<td>Unplanned use of cardiopulmonary bypass (CPB)</td>
</tr>
<tr>
<td>Unplanned use of CPB for haemodynamic support at any time during the TAVI procedure</td>
</tr>
<tr>
<td>Coronary obstruction</td>
</tr>
<tr>
<td>Angiographic or echocardiographic evidence of a new, partial or complete, obstruction of a coronary ostium, either by the valve prosthesis itself, the native leaflets, calcifications, or dissection, occurring during or after the TAVI procedure</td>
</tr>
<tr>
<td>Ventricular septal perforation</td>
</tr>
<tr>
<td>Angiographic or echocardiographic evidence of a new septal perforation during or after the TAVI procedure</td>
</tr>
<tr>
<td>Mitral valve apparatus damage or dysfunction</td>
</tr>
<tr>
<td>Angiographic or echocardiographic evidence of new damage (chordae papillary muscle, or to the leaflet) to the mitral valve apparatus or dysfunction (e.g. restrictions due to the THV) of the mitral valve during or after the TAVI procedure</td>
</tr>
<tr>
<td>Cardiac tamponade</td>
</tr>
<tr>
<td>Evidence of a new pericardial effusion associated with haemodynamic instability and clearly related to the TAVI procedure</td>
</tr>
<tr>
<td>Endocarditis</td>
</tr>
<tr>
<td>Any one of the following</td>
</tr>
<tr>
<td>Fulfilment of the Duke endocarditis criteria*</td>
</tr>
<tr>
<td>Evidence of abscess, paravalvular leak, pus, or vegetation confirmed as secondary to infection by histological or bacteriological studies during a re-operation</td>
</tr>
<tr>
<td>Findings of abscess, pus, or vegetation involving a repaired or replaced valve during an autopsy</td>
</tr>
<tr>
<td>Valve thrombosis</td>
</tr>
<tr>
<td>Any thrombus attached to or near an implanted valve that occludes part of the blood flow path, interferes with valve function, or is sufficiently large to warrant treatment. Note that valve-associated thrombus identified at autopsy in a patient whose cause of death was not valve-related should not be reported as valve thrombosis</td>
</tr>
<tr>
<td>Valve malpositioning</td>
</tr>
<tr>
<td>Valve migration</td>
</tr>
<tr>
<td>After initial correct positioning, the valve prosthesis moves upwards or downwards, within the aortic annulus from its initial position, with or without consequences</td>
</tr>
<tr>
<td>Valve embolization</td>
</tr>
<tr>
<td>The valve prosthesis moves during or after deployment such that it loses contact with the aortic annulus</td>
</tr>
<tr>
<td>Ectopic valve deployment</td>
</tr>
<tr>
<td>Permanent deployment of the valve prosthesis in a location other than the aortic root</td>
</tr>
<tr>
<td>TAV-in-TAV deployment</td>
</tr>
<tr>
<td>An additional valve prosthesis is implanted within a previously implanted prosthesis because of suboptimal device position and/or function, during or after the index procedure</td>
</tr>
</tbody>
</table>

TAVI: transcatheter aortic valve implantation; THV: transcatheter heart valve. *Durack et al. [72].

prosthetic valve EOA is defined not only by the size of the valve but also by the patient’s aortic valve/annular anatomy and procedural variables. Thus, well-established normal transcatheter valve gradients and EOAs based on pre-implant aortic annular dimensions do not currently exist. Clinicians should be aware of this variability when assessing a patient for transcatheter valve function and VARC-2 strongly recommends that the patient’s own initial post-implant study be used as a reference for serial comparisons.

The assessment of transcatheter valve dysfunction includes the immediate post-TAVI haemodynamics and the follow-up evaluation. The immediate post-TAVI evaluation documents initial valve appearance (position and circularity of the stent, and leaflet morphology and motion) and a comprehensive haemodynamic evaluation. Valve Academic Research Consortium-2 advocates using the integrative approach outlined in the algorithm shown in Figure 4 as part of a comprehensive haemodynamic evaluation by initially using one flow dependent (e.g. mean gradient) and one flow independent criterion (e.g. EOA) for the initial haemodynamic evaluation. If there is discordance between these measurements, then the DVI should be calculated. An abnormal DVI indicates possible prosthetic valve dysfunction. A normal DVI indicates intrinsically normal prosthetic valve function, and the indexed EOA can then be used to determine the reason for the initial measurement discordance. When the indexed EOA is low in the setting of a normal DVI, the patient probably has a prosthesis–patient mismatch (PPM), an indicator of the intrinsic relationship of the implanted valve to the cardiac output requirements of the patient [47]. Prosthesis–patient mismatch occurs in the setting of a morphologically normal valve and is considered to be haemodynamically insignificant if the indexed EOA is $>0.85\ cm^2/m^2$, moderate if between 0.65 and 0.85 cm$^2$/m$^2$, and severe if $<0.65\ cm^2/m^2$. However, for obese patients (body mass index $\geq 30\ kg/m^2$) lower criteria may be more appropriate (Table 10).

Transcatheter valve regurgitation

There is growing evidence suggesting a significant association of post-procedural paravalvular aortic regurgitation (AR) with short- and long-term mortality [48, 49]. As the duration of implanted transcatheter heart valves increases, valve durability and dysfunction become more crucial issues. Evaluating the presence and severity of regurgitation should include an assessment of both central and paravalvular components, with a combined measurement of ‘total’ aortic regurgitation (AR) reflecting the total volume load imposed on the LV (Table 10). The quantitative and semi-quantitative haemodynamic assessment of AR severity should be performed with Doppler echocardiography according to the
guidelines [39, 50, 51]. Colour Doppler evaluation should be performed just below the valve stent for paravalvular jets, and at the coaptation point of the leaflets for central regurgitation. Although all imaging windows should be used, the parasternal short-axis view is critical in assessing the number and severity of paravalvular jets. Whenever possible, the quantification of the prosthetic regurgitant volume, effective regurgitant orifice area, and regurgitant fraction (Table 10) should be performed [40, 51, 52]. The regurgitant volume may be calculated as the difference between the stroke volume across any non-regurgitant orifice (RVOT or mitral valve) and the stroke volume across the LVOT. It is important to realize that at this time the body of evidence supporting the numerical criteria used in Table 10 as well as Fig. 4 may be limited. These criteria should be used as guidelines for clinical decision-making and require further validation as our experience continues to expand.

**Follow-up assessments**

The follow-up assessment should also begin with valve imaging and documentation of changes in morphology. When determining whether a patient has developed haemodynamically significant structural valve failure, the patient’s own baseline echocardiographic parameters should be used as a reference. An increase in the mean gradient >10 mmHg, a decrease in the EOA >0.3–0.4 cm², or a reduction in the DVI >0.1–0.13 probably indicates a change in valve function and should trigger a comprehensive haemodynamic evaluation. Whenever valve dysfunction is suspected, the careful evaluation of valve morphology should confirm a structurally abnormal valve. In addition, measurement error must be excluded; the use of a consistent LVOT diameter for more accurate follow-up study comparisons is recommended. Finally, changes in ventricular morphology would be expected in the setting of long-standing significant valvular dysfunction and this parameter may support the clinical assessment of severity. Although the rate of moderate or severe regurgitation may appear to be less at the follow-up, this may be the result of attrition of the sickest patients. To assess such time trends, it is recommended to report an individual patient’s progression of regurgitation, in a table that provides changes between short-term and long-term regurgitation, including mortality [48].

**QUALITY OF LIFE**

**Quality of life evaluation in aortic stenosis**

New York Heart Association (NYHA) classification is limited by the discrete nature of the scale, which provides only modest

---

**Table 10: Prosthetic valve dysfunction**

<table>
<thead>
<tr>
<th>Prosthetic aortic valve stenosis*</th>
<th>Normal</th>
<th>Mild stenosis</th>
<th>Moderate/severe stenosis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Quantitative parameters</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peak velocity (m/s)</td>
<td>&lt;3 m/s</td>
<td>3–4 m/s</td>
<td>&gt;4 m/s</td>
</tr>
<tr>
<td>Mean gradient (mmHg)</td>
<td>&lt;20 mmHg</td>
<td>20–40 mmHg</td>
<td>&gt;40 mmHg</td>
</tr>
<tr>
<td><strong>Quantitative parameters</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Doppler velocity index</td>
<td>&gt;0.35</td>
<td>0.35–0.25</td>
<td>&lt;0.25</td>
</tr>
<tr>
<td>Effective orifice area</td>
<td>&gt;1.1 cm²</td>
<td>1.1–0.8 cm²</td>
<td>&lt;0.8 cm²</td>
</tr>
<tr>
<td>Effective orifice area</td>
<td>&gt;0.9 cm²</td>
<td>0.9–0.6 cm²</td>
<td>&lt;0.6 cm²</td>
</tr>
<tr>
<td><strong>Prosthesis–patient mismatch (PPM)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indexed effective orifice area#</td>
<td>&gt;0.85 cm²/m²</td>
<td>0.85–0.65 cm²/m²</td>
<td>&lt;0.65 cm²/m²</td>
</tr>
<tr>
<td>Indexed effective orifice area##</td>
<td>&gt;0.70 cm²/m²</td>
<td>0.90–0.60 cm²/m²</td>
<td>&lt;0.60 cm²/m²</td>
</tr>
<tr>
<td><strong>Semi-quantitative parameters</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diastolic flow reversal in the descending aorta—PW</td>
<td>Absent or brief diastolic</td>
<td>Intermediate</td>
<td>Prominent, holodiastolic</td>
</tr>
<tr>
<td>Circumferential extent of prosthetic valve paravalvular regurgitation (%)#</td>
<td>&lt;10%</td>
<td>10–29%</td>
<td>≥30%</td>
</tr>
<tr>
<td><strong>Quantitative parameters</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Regurgitant volume (ml/beat)</td>
<td>&lt;30 ml</td>
<td>30–59 ml</td>
<td>≥60 ml</td>
</tr>
<tr>
<td>Regurgitant fraction (%)</td>
<td>&lt;30%</td>
<td>30–49%</td>
<td>≥50%</td>
</tr>
<tr>
<td>EROA (cm²)</td>
<td>0.10 cm²</td>
<td>0.10–0.29 cm²</td>
<td>≥0.30 cm²</td>
</tr>
</tbody>
</table>

*In conditions of normal or near normal stroke volume (50–70 ml).

1These parameters are more affected by flow, including concomitant aortic regurgitation.

2For LVOT >2.5 cm, significant stenosis criteria is <0.20.

3Use in setting of BMI ≥30 kg/cm² (note: dependent on the size of the valve and the size of the native annulus).

4Use in setting of BMI <30 kg/cm².

5Not well-validated and may overestimate the severity compared with the quantitative Doppler.
resolution to detect clinically relevant changes. Moreover, since the NYHA class is assessed by an external body rather than the patient, it does not reflect the patient’s perspective. Thus, the NYHA class is more properly considered a measure of the functional status than the QOL.

The Minnesota Living with Heart Failure Questionnaire (MLHF) [53] and the Kansas City Cardiomyopathy Questionnaire (KCCQ) [54, 55] have a number of desirable properties for the evaluation of health-related QOL (HRQOL) in the setting of AS. Both instruments produce outcomes on a continuous scale, which improves responsiveness and sensitivity. Although only the MLHF has been specifically validated in patients with aortic valve disease, [56] preliminary experience with the KCCQ in patients undergoing TAVI has also demonstrated a high degree of responsiveness and internal consistency [57].

Recommended endpoints and timing of assessment

Valve Academic Research Consortium-2 recommends that a comprehensive assessment of HRQOL for patients undergoing TAVI incorporate both a heart failure-specific measure (such as the KCCQ or MLHF) as well as one or more generic measures (such as the Medical Outcomes Study Short-Form 36 (SF-36), the Short-Form 12 (SF-12), or the EuroQOL (EQ-5D)) [58–60]. The disease-specific measures offer improved sensitivity/responsiveness as well as clinical interpretability, whereas the inclusion of a generic health status measure is useful because it captures some additional domains. Furthermore, generic measures can enhance the comparability across different diseases and populations and can be used to compare patients with population-level benchmarks.

For the comparison of TAVI vs. SAVR (or for the comparison of alternative access sites for TAVI), we recommend that early QOL assessment be performed at 2 weeks, 1 month, and 3 months using a combination of generic instruments and pain scales (e.g., visual analogue scale) to assess the early recovery process. The evaluation of the QOL at an intermediate time point (e.g., 6 months) could also be considered in order to confirm that QOL recovery is complete by this stage. At later time points (1–5 years), the use of heart failure-specific instruments to identify the consequences of long-term valve performance may be more useful. Finally, the assessment of cognitive function at later time points (1–5 years) may be valuable for the comparison of surgical vs. catheter-based techniques, although these endpoints generally require highly specialized and demanding neuropsychiatric testing [61]. In contrast, for the comparison of alternative TAVI systems (as may be expected in the near future), HRQOL assessment should focus mainly on heart failure-specific endpoints at intermediate and later time points (1–5 years), wherein between-device differences in the haemodynamic performance or structural valve deterioration may emerge. The inclusion of disease-specific QOL measures in these studies can also provide insight into the consequences of valve-related complications such as the need for pacemaker insertion.
Additional considerations

It is essential to ensure complete ascertainment of HRQOL at each time point, as missing data cannot be retrieved retrospectively and statistical adjustment techniques (e.g., multiple imputation) that assume that data are ‘missing at random’ may not be adequate. Differential mortality between two treatments may complicate the interpretation of QOL results since the QOL may appear to ‘improve’ over time even with an ineffective therapy simply because of attrition of the sickest patients. The use of categorical endpoints that characterize outcomes as favourable (e.g., survival AND improvement of QOL endpoints) [44, 57] or endpoints that integrate survival and the QOL (e.g., quality-adjusted life expectancy) may provide more interpretable results. In such cases, reporting the outcomes in both ways (i.e., among the entire study cohort and separately among only the surviving patients) will provide the most complete description of the results.

COMPOSITE ENDPOINTS

Rationale and caveats

Comparisons of the success, safety, and effectiveness with achievable study cohort sample sizes may at times require the use of composite endpoints. However, it is important that composites contain components that have roughly similar impacts on the patient. A family of single endpoints tending in the same direction may, as a family of hypotheses, be statistically significant when individual endpoints are not.

Each post-procedural event has a different temporal risk profile (hazard function) modulated by different risk factors. Therefore, traditionally, the evaluation of the safety and efficacy of procedures has focused on in-hospital events (complications and morbidity), events within 30 days of the procedure, and ‘late’ events.

Specific composite endpoints

The assessment of TAVI, SAVR, and their alternatives or new devices should include device, procedure, and patient-oriented endpoints. These endpoints have been devised to be applicable to both TAVI and SAVR. Previous clinical trials have used the all-cause mortality at 1 year as the primary clinical endpoint. Owing to the emergence of stroke as an important clinical event, future trials should also require the composite of all-cause mortality and disabling stroke as a primary or secondary endpoint.

The first VARC document proposed three composite endpoints: device success, early safety, and clinical efficacy. Valve Academic Research Consortium-2 goes beyond the early and intermediate experience of TAVI, drawing upon prior surgical AVR guidelines to include time-related safety endpoints [62]. Therefore, VARC-2 recommends a new composite endpoint, time-related valve safety, which combines valve dysfunction, endocarditis, and thrombotic complications of the prosthesis (Table 11).

DISCUSSION

Although the original VARC standardized endpoint definitions were fundamentally useful and have been widely adopted,
Therefore, it becomes increasingly important to identify those patients who benefit from either treatment. Specific risk categories have been defined to allow universal clinical study designs and outcome comparisons.

Changes and additions that have been applied to improve the interpretation of clinical endpoint definitions and provide further insights on TAVI-related outcomes are as follows: (i) risk stratification should be done by a dedicated ‘heart team’ and include other factors (e.g. frailty, porcelain aorta) beyond the traditional risk scores, and should take into account co-existing conditions; (ii) immediate procedural death has been added to capture intra-procedural events that result in immediate or consequent death; (iii) stroke ascertainment requires the use of precise definitions, standardized assessments, close collaboration with neurology experts including the consideration of acute stroke management, and has been re-categorized as non-disabling or disabling; (iv) detailed documentation of the etiology of strokes and concomitant therapies is needed to provide insights into the multi-factorial nature of acute, early, and late strokes; (v) closure device failure is now a separate category within vascular complications, and if unplanned percutaneous or surgical intervention does not lead to adverse outcomes, these are not considered as a major vascular complication per se; (vi) the time for AKI diagnosis has been extended from 72 h to 7 days; (vii) AKI is diagnosed according to AKIN guidelines, which include classification by the urine output to detect a wider range of aetiologies; (viii) peri-procedural myocardial infarction is defined by troponin or CK-MB elevation and the troponin threshold has changed from 10× ULN to 15× ULN based on recent data; [19] (ix) assessment of conduction disturbances and arrhythmias has been reinforced; [65–68] (x) new definitions for several TAVI-related complications and valve malpositioning are reported; (xi) echocardiography parameters of prosthetic valve stenosis and regurgitation have been updated and now include the assessment of the prosthesis–patient mismatch; (xii) for the QOL assessment, VARC-2 recommends the use of both heart-failure-specific and generic measures during the follow-up between 30 days and 5 years to fully assess the impact of the procedure and the durability of clinical benefit.

These definitions can be used in studies comparing TAVI to surgical AVR, as well as in future trials comparing first generation to next generation TAVI devices.

The composite endpoint of device success has specifically been criticized for being too strict with regard to valve performance; for example, an AWA >1.2 cm² seems unachievable in patients with smaller body habitus [5]. The current VARC-2 definition therefore corrects for the body surface area so that valve performance is now assessed through the indexed EOA. It is notable that valve-in-valve procedures for failing bioprostheses will frequently have a low device success, even with this modified definition [69]. Considering that stroke has emerged as an important concern, the composite of all-cause mortality and disabling stroke should be considered as a primary or secondary endpoint in future trials. Two ongoing large randomized trials [PARTNER II (NCT01314313) and SURTAVI (NCT01586910)] are already incorporating these composite endpoints.

With longer follow-up duration, it becomes more critical to include time-related valve safety composite endpoints. This will eventually provide linearized rates of complications with transcatheter valves, known as ‘objective performance criteria’, as has been used to evaluate surgical valves [70].

With this VARC-2 document, we have provided further standardization of endpoint definitions and hope that the adoption of these criteria will continue to increase, ultimately leading to improved comparability and interpretability of the study results.

**Funding**

Grants have been provided to the ARC Board including representatives of Cardialysis, the Cardiovascular Research Foundation, Duke Clinical Research Institute, and Harvard Clinical Research Institute to cover the costs of travel, meeting rooms, and lodging for academic attendees at the Washington and Rotterdam meetings by Abbott Vascular, Boston Scientific, Direct Flow Medical, Edwards Lifesciences, Heart Leaflet Technologies, Medtronic Corporation, and St. Jude Medical.

**Conflicts of interest:** N. Piazza has received consultancy fees from Medtronic, his institution has received grants/grants pending from Medtronic. E.H. Blackstone has received study support from Edwards Lifesciences consultancy fees from Edwards Lifesciences. D.J. Cohen has received consultancy fees from Medtronic, his institution has received grants/grants pending from Medtronic and Edwards Lifesciences. G.A van Es is an employee of Cardialysis BV, Netherlands. M.W. Krucoff has received study support from Edwards Lifesciences. S. Kodali is a Board member of St. Jude Medical and Thubrikar Aortic Valve and has received consultancy fees from Medtronic and Edwards Lifesciences. R. Mehran has received consultancy fees from Astra Zeneca, Jansen (Johnson & Johnson), Regado, Abbott Laboratories, Merck Sharpe & Dohme Corp., Mayo Medical. Her institution has received grants/grants pending from BMS/Sanofi, The Medicines Company, Lilly/Daichi Sanko. J. Rodes-Cabau has received consultancy fees from Edwards Lifesciences, St. Jude Medical. J.G. Webb has received consultancy fees from Edwards Lifesciences, his institution has received grants/grants pending from Edwards Lifesciences. S. Windecker has received speakers bureaus fees from Edwards Lifesciences and Medtronic, his institution has received a Swiss National Science Foundation Grant (32003B_135807) and has grants/grants pending from Edwards Lifesciences and Medtronic. M.B. Leon is on the advisory Board for Edwards Lifesciences. The others authors have declared to have no conflict of interests for this paper. The VARC meetings involved members of the Interventional Cardiology Devices Branch, of the Office of Device Evaluation, Center for Devices and Radiological Health, USFDA. The opinions or assertions herein are the private views of the authors and are not to be construed as reflecting the views of the FDA.

**REFERENCES**


APPENDIX 1

VARC contributing groups

(1) Academic Research Organizations

Cardiovascular Research Foundation (New York, NY, USA)

Duke Clinical Research Institute (Durham, NC, USA)

Harvard Clinical Research Institute (Boston, MA, USA)

European Society of Cardiology

Society of Thoracic Surgeons
APPENDIX 2

VARC participants

(1) Clinical Research Organizations
(i) Cardialysis/Erasmus MC, Rotterdam, Netherlands
   Head, SJ
   Moviel, MA
   Serruys, PW
   Van Es, GA
   Van Mieghem, NM
   Vranckx, P

(ii) Cardiovascular Research Foundation, New York, NY, USA
    Hahn, RT
    Kirtane, AJ
    Leon, MB
    Maxwell, Y
    Mehran, R

(iii) Duke Clinical Research Institute, Durham, NC, USA
    Alexander, KP
    Douglas, DS
    Krucoff, MW
    Petersen, J

(iv) Harvard Cardiovascular Research Institute, Boston, MA, USA
    Cutlip, DE

(2) Cardiologists
   Borer, JS: Howard Gilman Institute for Heart Valve Diseases, Brooklyn, NY, USA
   Cohen, DJ: Saint Luke’s Mid America Heart Institute, Kansas City, MO, USA
   Holmes, DR Jr: Mayo Clinic Rochester, Rochester, MN, USA
   Iung, B: CHU Bichat, Paris, France
   Maikar, RR: Cedars-Sinai Heart Institute, Los Angeles, CA, USA
   Piazza, N: German Heart Center, Munich, Germany; and
   McGill University Health Center, Montreal, Canada
   Popma, JJ: Beth Israel–Deaconess Medical Center, Boston, MA, USA
   Rodés-Cabau, J: Quebec Heart and Lung Institute, Quebec, Canada
   Thomas, M: Guys and St Thomas Hospital, London, UK
   Tuzcu, EM: Cleveland Clinic Foundation, Cleveland, OH, USA
   Vahanian, A: CHU Bichat, Paris, France
   Webb, JG: St Paul’s Hospital, Vancouver, BC, Canada
   Windecker, S: University Hospital Bern, Bern, Switzerland

(3) Surgeons
   Adams, DH: Mount Sinai Medical Center, New York, NY, USA
   Cameron, DE: Johns Hopkins Medical Institutions, Baltimore, MD, USA
   Fontana, GP: Lenox Hill Heart and Vascular Institute, New York, NY, USA
   Kappetein, AP: Erasmus MC, Rotterdam, Netherlands
   Mack, MJ: Baylor Health Care Systems, TX, USA
   Maisano, F: San Raffaele Hospital, Milan, Italy
   Miller, DC: Stanford University, CA, Stanford, USA
   Moat, NE: Royal Brompton and Harefield National Health Service (NHS) Foundation Trust, London, UK
   Walther, T: Kerckhoff Heart Center Bad Nauheim, Bad Nauheim, Germany

(4) Echocardiographers
   Geleijnse, ML: Erasmus University Medical Center, Rotterdam, Netherlands

(5) Neurologists
   Brott, TG: Mayo Clinic, Jacksonville, FL, USA
   Van der Worp, H: University Medical Center Utrecht, Utrecht, Netherlands

(6) Statisticians
   Blackstone, EH: Cleveland Clinic Foundation, Cleveland, OH, USA

(7) US Food and Drug Administration
   Agnel, F
   Dunn, B
   Getzoff, N
   Laschinger, J
   Patel, S
   Sansing, V
   Sastry, A
   Swain, J
   Zuckerman, B

(8) Industry representatives
   Akin, J: Edwards Lifesciences, Orange, CA, USA
   Allocco, D: Boston Scientific, Minneapolis, MN, USA
   Armitage, T: Medtronic CardioVascular, Minneapolis, MN, USA
   Bebeau, V: St Jude Medical, Minneapolis, MN, USA
   Concepcion, B: Boston Scientific, Minneapolis, MN, USA
   Fonseca, T: Medtronic CardioVascular, Minneapolis, MN, USA
   Robb, R: Medtronic CardioVascular, Minneapolis, MN, USA
   Schroeder R: Heart Leaflet Technologies, Minneapolis, MN, USA
   Sethuraman, B: Abbott Vascular, Santa Clara, CA, USA
   Sheahan, B: Direct Flow Medical, Santa Rosa, CA, USA
   Tatarek, N: St Jude Medical, Minneapolis, MN, USA

(9) Observers: other
   Fitzgerald, S
   Carroll, JD
   Edwards, FH
   Lansky, AJ
   Prager, RL